May 13, 2021 / 08:15PM GMT
Jason Gerberry - Bank of America - Analyst
Good day, everybody. Thank you for joining us at the Bank of America annual healthcare conference being conducted virtually this year. My name is Jason Gerberry. I'm one of the biopharma analysts at BofA. And I'm pleased to be introducing our next company presenter, Lyra Therapeutics; and CEO, Maria Palasis, who has some slides that she's going to run through. So I'm going to hand the mic over to Maria. So Maria, it's all yours.
Maria Palasis - Lyra Therapeutics - President and CEO
Great, thank you, Jason. It's great to be here. Thank you for the invitation. And I am going to start on slide number 3, investment summary.
So we, now, at Lyra Therapeutics have completed three clinical studies on LYR-210. Both of the products that are in development right now are targeting Chronic Rhinosinusitis. In the US, there is 14 million patients that have CRS, and globally, it's a large problem throughout the world.
In the US, there are no FDA approved medicines to treat the indication of CRS. And in fact, the
Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers